A Randomized Phase 2 Study to Evaluate the Efficacy Between Only Radiotherapy Versus CCRT With Temozolomide in Newly Diagnosed Grade III Gliomas Without 1p/19q Codeletion
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 06 Jul 2017
At a glance
- Drugs Temozolomide (Primary)
- Indications Anaplastic astrocytoma; Glioma; Oligodendroglioma
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 08 Jul 2015 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.
- 10 Apr 2013 New source identified and integrated (Korean Clinical Trials Register; KCT0000700).